SCHEMBL3544859

SCHEMBL3544859

CC(C)(C)c1cc(C(=O)Nc2cccnc2)c(NC(=O)Nc2ccc(Cl)cc2)s1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
RAB9A P51151 2/20 0.60
MAPK14 Q16539 4/20 0.54
NAMPT P43490 2/20 0.54
CYP11B2 P19099 3/20 0.53
RPS6KB1 P23443 1/20 0.51
KCNMA1 Q12791 1/20 0.51
LMNA P02545 2/20 0.50
MAPT P10636 2/20 0.50
CYP11B1 P15538 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CNR1 P21554 1/20 0.50
FLT3 P36888 1/20 0.49
NPC1 O15118 2/20 0.48
GRIK1 P39086 1/20 0.48
TP53 P04637 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543192 0.79 MAPK14 (0.65) MEN1KMT2ARAB9AMAPK14RPS6KB1
SCHEMBL9190814 0.78 KMT2A (1.00) MEN1KMT2ARAB9ANAMPTCYP11B2
SCHEMBL27308657 0.74 MEN1 (0.75) MEN1KMT2ARAB9ANAMPTCYP11B2
SCHEMBL13315251 0.73 RPS6KB1 (0.53) MEN1KMT2AMAPK14NAMPTRPS6KB1
SCHEMBL12334658 0.72 CYP11B2 (0.86) MEN1KMT2ARAB9ANAMPTCYP11B2
SCHEMBL23343643 0.71 NAMPT (0.79) MEN1KMT2ARAB9ANAMPTLMNA
SCHEMBL13315236 0.71 MAPK14 (0.56) MAPK14RPS6KB1
SCHEMBL13315249 0.71 MAPK14 (0.52) MAPK14NAMPTRPS6KB1LMNAHTT
SCHEMBL3224242 0.70 MAPK14 (0.66) MEN1KMT2AMAPK14RPS6KB1LMNA
SCHEMBL9191584 0.70 MEN1 (0.70) MEN1KMT2ARAB9ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741479-B2 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. (US) 2010-06-22 US claimed
EP-1828169-A2 UREA INHIBITORS OF MAP KINASES Locus Pharmaceuticals, Inc. (US) 2007-09-05 EP claimed
US-20060167247-A1 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. 2006-07-27 US claimed
WO-2006062982-A2 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 WO claimed
US-7741479-B2 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. (US) 2010-06-22 US disclosed
US-7741479-B2 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. (US) 2010-06-22 US disclosed
EP-1828169-A2 UREA INHIBITORS OF MAP KINASES Locus Pharmaceuticals, Inc. (US) 2007-09-05 EP disclosed
US-20060167247-A1 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. 2006-07-27 US disclosed
WO-2006062982-A2 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167247-A1 Urea inhibitors of MAP kinases MAPK1, MAP3K1, MAP3K20 MEN1 4186/4885KMT2A 2250/4885RAB9A 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.